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Dermaseptins are a group of α-helical shaped polycationic peptides isolated from the 
Hylid frogs, with antimicrobial effects against bacteria, parasites, protozoa, viruses in vitro. 
Besides, anti-tumor effects have been demonstrated. However, few animal experiments 
and no clinical trials have been conducted thus far. This review summarizes the current 
knowledge on the pharmacology, ethno pharmacology, effectivity against infectious 
pathogens and tumors cells and the mechanism of action of the Dermaseptins. Future 
research should focus on further clarification of the mechanisms of action, the effectivity 
of Dermaseptins against several cancer cell lines and their applicability in humans.
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INTRODUCTION
Dermaseptins (DRSs) are a family of peptides that are part of the skin secretions of several Hylid 
frogs, particularly from the Agalychnis and Phyllomedusa family (Nicolas and Amiche, 2006; Amiche 
et al, 2008). In 1991, the first DRS was identified and characterized as a peptide rich in basic amino 
acids with a high propensity to adopt an α-helical structure in a hydrophobic medium (Mor et al, 
1991). The DRS-S1 was purified by reverse phase high-pressure liquid chromatography (RP-HPLC) 
from a skin extract of the Phyllomedusa sauvagii and sequenced by Edman’s method. By now, there 
are more than a hundred DRS-like peptides classified in the large family of DRSs that share a strong 
identity in the cDNA sequences encoding their biosynthetic precursors (Nicolas and El Amri, 2009).
DRSs are often classified as antimicrobial peptides (AMPs), since they show effectivity in vitro 
against some gram positive and gram negative bacteria, parasites, yeasts, protozoa, viruses and 
display immune modulatory effects (Mor et al., 1994a; Mor et al., 1994b; Strahilevitz et al., 1994; 
Charpentier et al., 1998; Brand et al., 2002; Navon-Venezia et al., 2002; Brand et al., 2006; Conceicao 
et al., 2006; Conlon et al., 2007; Leite et al., 2008; Galanth et al., 2009; Nicolas and El Amri, 2009; 
Jiang et al., 2014; Zairi et al., 2014; Huang et al., 2017). Beside these antimicrobial properties, DRSs 
show activity against several human cancer types (Charpentier et al., 1998; Conlon et al., 2007; 
Nicolas and El Amri, 2009; Galanth et al., 2009; Van Zoggel et al., 2012; Shi et al., 2016; Huang 
et al., 2017; Dos Santos et al., 2017; Zhu et al., 2018) and can therefore be classified as an anticancer 
peptide as well.
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In view of the current increasing bacterial resistance to 
conventional antibiotics (Laxminarayan et al., 2013) the demand 
for novel antibacterial pharmaceuticals is high. Likewise, there 
is a need for novel anti-tumor treatments as cancer is rapidly 
becoming the leading cause of death in the Western world 
and conventional therapeutics are both cytotoxic and prone to 
therapy resistance due to microevolution of the tumor tissue 
(Corrie, 2008; Colak and Medema, 2014).
The aim of this review is to summarize the current knowledge 
on DRSs, to elaborate on the ethnopharmacology, the potential 
therapeutic values with respect to their anti-microbial and anti-
tumor potency, and to suggest future directions for research. We 
thereby restricted ourselves to DRSs (sensu stricto) according to 
the nomenclature proposed by Amiche et al. (2008).
ETHNOPHARMACOLOGY IN PEPTIDE 
DISCOvERY
Many plants and animal products have yet found their way from 
traditional use to Western medicine leading to the discovery 
of for example morphine, codeine, quinine, aspirin, curare, 
pilocarpine and ACE-inhibitors (Bisset, 1991; Alves and Alves, 
2011; Dias et al., 2012). Likewise, DRS-B’s from the Phyllomedusa 
bicolor secretions are yet known to be applied for human use in 
traditional medicine. This Phyllomedusa bicolor is an Amazonian 
amphibian found in the forests of Brazil, the Guianas, Venezuela, 
Colombia, Peru, and Bolivia. The secretions of this frog are 
referred to by ‘Kambo’,’Kampu, or ‘Sapo’, and are used by natives 
as a medicine and part of a cleansing ritual. The use of Kambo 
by South American Indians was first described by Constantin 
Tastevin in 1925 in the Kachinaua, Kurina, and the Kanamari 
tribes (De Lima and Labate, 2008). Later, the traditional use of 
kambo was also documented in the Katukina tribe, the Mayoruna 
tribe, and the Matse tribe (De Lima and Labate, 2008; Gorman, 
2015). Other DRS secreting frogs have not been documented to 
be useful in rituals.
The Kambo-ritual is characterized by an immediate and 
short-lived physical response followed by a longer lasting mental 
and minor physical effects. The Indians ‘harvest’ the frog by 
collecting the secretion from a live frog and transfer its secretions 
to a bamboo stick. The medicine may then be used to cure or 
prevent illness, to expel ‘panema’ (bad spirit), or even to induce 
an abortion (Gorman, 2015). When unlucky in hunting Kambo 
reportedly increases stamina, and sharpens senses during long 
hunts. Application involves burning dots on the skin, usually on 
arms and/or legs, and sticking a small dose (10 mg) ‘dot’ on the 
open wound. The symptoms are severe and immediate; violent 
nausea, vomiting, diarrhea, edema of the face and headaches. 
Symptoms last until the secretion is removed from the wound 
usually after 15–20 minutes.
Besides its traditional use in the Amazon, Kambo has 
found its way into the Western alternative healing scene as 
well. While the reports on the beneficial effects of this ritual 
are numerous and range from relieving symptoms of pain 
syndromes, autoimmune diseases, skin disease, and cancer 
to substance abuse and depression (Hesselink, 2018), so are 
the accounts of adverse effects of participating in a rite, with 
or without experienced guidance. These include a transient 
syndrome of inappropriate antidiuretic hormone secretion 
(Leban et al., 2016), presumed drug induced liver injury 
in a chronic alcoholic (Pogorzelska and Lapinski, 2017), 
sudden death upon chronic kambo use in which autopsy 
revealed underlying heart disease possibly related to reduced 
myocardial perfusion (Aquila et al., 2018) and delayed kambo 
related symptoms in a 24-year-old woman 22 hours after the 
ritual (Li et al., 2018).
The short-lasting effects of kambo are related to a diversity of 
biologically active peptides besides DRS including Phyllokinin 
(a bradykinin), Phyllomedusa (a tachykinin), Sauvagine 
(vasodilator), Caerulin (a CCK like peptide) and Deltorphin/
Demorphin (opioid receptor agonists). Studies on these 
peptides have contributed greatly to our knowledge concerning 
the μ/δ-opioid and serotonin receptor (Erspamer et al., 1993), 
but are beyond the scope of this review. Many of the immediate 
effects of Kambo can be explained by peptides in the frog-
secretion. Vasoactive properties of some of these peptides 
for example might contribute to the rapid absorption of the 
secretion into the fresh burn. Amongst these peptides, DRS is 
the primary candidate for the anti-microbial effects reported 
upon the use of Kambo.
STRUCTURAL AND PHARMACOLOGICAL 
ANALYSIS OF THE DRS FAMILY
Even though each DRS has a unique amino acid sequence 
and selectivity patterns towards microorganisms and tumors, 
there are also a lot of pharmacological similarities. Figure 1 
shows the amino acid sequence alignment of 57 DRSs 
sequences extracted from the antimicrobial peptide databases 
(http://aps.unmc.edu/AP/main.php). There is amino-acid 
sequence similarity within DRS from the same frog (DRS-B1–
B6; 33–62%) (Charpentier et al., 1998), but also between DRS 
from different species (DRS-B1 and DRS-S1; 81%, DRS-B2, 
and DRS-D 84.8%) (Mor et al., 1994b; Auvynet et al., 2008). 
They are mostly rather short peptides (21–34 residues) with 
a highly-preserved tryptophan residue on the 3rd position 
from the N-terminus (Nicolas and El Amri, 2009) except for 
DRS-S10, DRS-S13, DRS-C3, and DRS-A4. DRSs can be fitted 
into an amphipathic α-helix with their hydrophobic residues 
on one face and the polar cationic residues in cluster on the 
opposite face. They usually do this is an anionic environment, 
or under the influence of certain phospholipids (Hoskin 
and Ramamoorthy, 2008). These charged clusters tend to 
differ among DRS, for example; DRS-B1 has a narrow polar 
face of a mean radial angle of 115°, DRS-B2 has a polar face 
covering almost half of the helix; 175° and DRS-S1 a polar 
face of 145° (Mor et al., 1994a). Furthermore, they show 
great variation in net charge and density of charge. DRS-S9 
seems to be an exception as it has a highly hydrophobic core 
flanked by cationic residues (Lequin et al., 2006; Caillon et al., 
2013). Thus far, several DRS have been in vitro tested for their 
activity against various microorganisms (Lorin et al., 2005; 
Savoia et  al., 2010; de Moraes et al., 2011; van Zoggel et  al., 
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2012a; Zairi et al., 2014), DRS-B2 has been tested in mice 
and rats in vivo for tumor and antimicrobial activity (Navon-
Venezia et al, 2002; Huang et al., 2017). Though reportedly 
administered to humans in non-experimental settings (DRS-
B’s), robust data on pharmacokinetics, efficacy and safety in 
humans are currently lacking.
RESEARCH IN INFECTIOUS DISEASES
Antibacterial Activity of Peptides From the 
DRS Family
In 1991, Mor was the first to publish on the anti-microbial 
properties of DRS (Mor et al., 1991). DRS-B1 and S1 show in 
FIGURE 1 | Amino acid sequence alignment of 57 DRS peptides (http://aps.unmc.edu/AP/main.php) using CLUSTAL O (1.2.4) multiple sequence alignment 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). The letters represent an amino acid according to conventional nomenclature. The dashes are introduced to optimize 
amino-acids alignments. Blue colors indicate a well-preserved amino acid (>55% of identity), green colors indicate higher rates of preservation within this DRS group 
(>80% of identity).
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vitro activity against gram positive and negative bacteria with 
various specificities (Strahilevitz et al., 1994). Derivatives 
of DRS-S4, DRS-CA1, DRS-DU1 and DRS-PH show in 
vitro activity against Staphylococcus aureus (including 
the methicillin resistant strain), Pseudomonas aeruginosa 
and E. coli, even when they are formed in biofilm (Navon-
Venezia et al., 2002; Zairi et al., 2014; Liu et al., 2017; Zhu 
et al., 2018). Though less cytotoxic compared to conventional 
antibiotics (Zairi et al., 2014), the DRS-S4 derivatives used 
demonstrated similar or even higher efficacy in vitro(Porat 
et al., 2006; Rotem et al., 2006; Marynka et al., 2007; Jiang 
et al., 2014). These results were confirmed in vitro and in 
vivo with mice infected with P. aeruginosa (Navon-Venezia 
et al., 2002; Marynka et al., 2007) and in various incubation 
media varying in temperature and acidity (Rydlo et al., 2006). 
Table 1 provides an overview of the activity of a few DRSs 
against selected pathogens frequently related to infections and 
associated with anti-biotic resistance. For a complete list of 
DRSs and pathogens with corresponding MIC and source, we 
refer to Supplementary Table 1s.
Antiviral Activity of Peptides From the 
DRS Family
In addition to the antibacterial efficacy, DRS-S1 (and 
derivatives) show activity against pathogens causing genital 
infections such as human papilloma virus (HPV) and herpes 
simplex virus (HSV) (Savoia et al., 2010). Furthermore, 
modified DRS-S4 has shown antiviral activity against Herpes 
Simplex Virus 1 & 2, including the acyclovir resistant strain in 
vitro (Belaid et al., 2002; Bergaoui et al., 2013). For the activity 
peaks in case of DRS administration prior to incubation with 
the virus, interference early in the viral replication cycle is 
hypothesized (Belaid et al., 2002; Mechlia et al., 2018). DRS-
S4 and S9 both demonstrate in vitro activity against HIV-1 
virus (Lorin et al., 2005; Wang et al., 2010) by inhibition of 
HIV attachment to endometrial cells, uptake by the dendritic 
cells and subsequent transmission to T-cells (Lorin et al., 
2005). Again, interference of DRS-S4 in an early phase of virus 
replication is suggested as less reduction of HIV is observed 
once the T-cells have been infected. Substitution of methionine 
for lysine on the 4th position DRS-S4 to reduce cytotoxicity to 
mammalian cells, did not affect the anti-HIV activity observed 
(Lorin et al., 2005). More recently, DRS-S4 has shown effectivity 
against Rabies virus in mice (Mechlia et al., 2018).
Antifungal Activity of Peptides From the 
DRS Family
DRSs also show activity against fungi in vitro. So far, DRS-B1-B2, 
DRS-S1-S5 DRS-O1, DRS-CA1 DRS-DU1 all demonstrate 
cytotoxicity against Candida albicans (Strahilevitz et al., 1994; 
Mor et al., 1994a; Mor et al., 1994b; Leite et al., 2008; Nicolas 
and El Amri, 2009; Shi et al., 2016; Huang et al., 2017; Zhu 
et al., 2018). In particular, DRS-S3 shows anti-fungal activity 
by means of triggering apoptosis (Morton et al., 2007). In 
Aspergillus fumigates, cytotoxic activity was demonstrated for 
DRS-B1-B2 and DRS-S1, but not DRS-S5. Minimal inhibitory 
TABLE 1 | Effectivity of Dermaseptins in vitro against various pathogens.
E. coli E. faecalis P. aeruginosa S. aureus C. albicans A. fumigatus Human 
erythrocytes
DRS-B1
DRS-B2
DRS-B3
DRS-B4
DRS-S1
DRS-S2
DRS-S3
DRS-S4
DRS-S4 K4-S4(1-16)
DRS-S5
DRS-PH
DRS-H3
DRS-L1
DRS-O1
DRS-DI06
DRS-CA1
DRS-DU1
DRS-PD1
DRS-PD2
DRS-PS4
This table gives an overview of the effectivity of DRS activity against a selected number of pathogens. Cells are colored dark green if: more than one study agrees on high 
activity (MIC <10 μM); light green if: 1 study finds high activity (MIC <10 μM); orange if studies do not agree on MIC; red if one or more studies agree on low activity (MIC > 
10 μM); white indicates that there was no published data available. In the Human erythrocyte column, the opposite is instinctively true; green color indicates low, and red 
indicates high activity (Strahilevitz et al., 1994; Mor et al., 1994a; Mor et al., 1994b; Carpentier et al., 1998; Brand et al., 2002; Navon-Venezia et al., 2002; Conceicao et al., 
2006; Brand et al., 2006; Conlon et al., 2007; Galanth et al., 2009; Zairi et al., 2014; Huang et al., 2017; Nicolas and El Amri, 2009; Leite et al., 2008; Jiang et al., 2014; De 
Assis et al., 2016; Shi et al., 2016; Belmadani et al., 2018; Zhu et al., 2018; Shams et al., 2019) for more information, see Supplementary Table S1.
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concentrations (MIC) ranging from 3.1 μM to 30 μM were 
observed. In addition, others (Belmadani et al., 2018) found 
that DRS-S1 inhibits C. albicans in biofilm formation when 
using concentrations of 100 μM. These findings are summarized 
in Table 1.
Antiparasitic Activity of Peptides From the 
DRS Family
Finally, DRS-S3 and S4 derivatives appear able to target malarial 
parasites within a host erythrocyte without disrupting the host 
(Ghosh et al., 1997; Krugliak et al., 2000; Dagan et al., 2002). 
In addition DRS from the Phyllomedusa oreades (DRS-O1) has 
shown activity against Schistosoma mansoni (de Moraes et al., 
2011), Trypanosoma cruzi (Brand et al., 2002; Leite et al., 2005) 
and Leishmania amazonesis (Brand et al., 2006).
RESEARCH IN ONCOLOGY
Parallel to the efficacy against microbials, efficacy against tumor 
cells has been studied as well (Hoskin and Ramamoorthy, 2008; 
Balandin et al., 2016). Table 2 summarizes the data published on 
the impact of DRS on selected cancer cell lines.
DRS-B2 for example, shows a dose dependent growth 
inhibition of prostatic adenocarcinomas (GI50 = 0.71–2.65µM) 
and some pancreatic cancer cell lines. Administration of 1µM 
DRS-B2 was enough for 50% reduction in colony formation in 
both prostate adenoma and mammary carcinoma cell lines (van 
Zoggel et al., 2012). No growth inhibition on glioblastoma and 
mammary carcinoma cell lines was observed (van Zoggel et al., 
2012; Dos Santos et al., 2017). At a concentration of 15 µM, no 
activity against stromal prostate fibroblasts and skin fibroblasts 
was observed, indicating low cytotoxicity in surrounding tissue 
(van Zoggel et al., 2012; Dos Santos et al., 2017). In vivo, DRS did 
not arrest human PC3 tumor growth in mice, but inhibited growth 
with more than 50% vs. controls attributed to a 24% reduction of 
angiogenesis in tumors of treatment groups, quantified by CD34+ 
positive stained endothelial cells. No side-effects or differences in 
total blood count were observed (van Zoggel et al., 2012).
Furthermore, DRS-PH shows IC50’s of 0.69 µM, 2.01 µM, and 
2.36 µM, against breast cancer adenoma (MCF-7), non-small cell 
lung carcinoma (NSCLC) (H157), and glioblastoma (U251MG) 
in vitro respectively (Huang et al., 2017). For DRS-PH less efficacy 
was observed against PC3 cell lines, compared to the activity 
profile of DRS-B2. DRS-PH did also show some cytotoxicity 
against human dermal endothelium, and mammalian red blood 
cells (Huang et al., 2017).
MECHANISM OF ACTION
The mode of action by which antimicrobial peptides kill microbes 
is mainly known for α-helix cationic peptides which have been 
extensively studied (Amiche and Galanth, 2011; Melo and 
Castanho, 2012; Bahar and Ren, 2013). Two models explaining the 
interaction of α-helical cationic AMPs with membranes have been 
proposed: the barrel-stave model (Ehrenstein and Lecar, 1977) and 
the carpet or carpet model (Pouny et al, 1992), both taken over 
by Shai in 1999 (Shai, 1999). The cationic antimicrobial peptides, 
destructured in aqueous media, adopt an α-helical structure in 
contact with the plasma membranes of the host cell and then interact 
with the negative charges of the components of the membrane 
surface (Zasloff, 2002). After binding, the peptide will disrupt the 
permeability of the membrane and either cause the death of the 
microorganism or enter the cell compartment and interact with 
intracellular targets. Note that most cationic antimicrobial peptides 
have a direct action on the membrane of bacteria, but some such 
as buforine II act intracellularly (Park et al, 1998). In most of the 
mechanisms described, the binding of antimicrobial peptide to the 
membrane is followed by permeabilization of the membrane, which 
alone can cause cell death, or as a step in more complex processes.
In addition, very few studies on the anti-tumour action 
mechanism(s) of antimicrobial peptides have been conducted. 
The most important results show that their oncolytic mechanisms 
include: (i) induction of necrosis via cell membrane lysis, (ii) 
TABLE 2 | Overview of the activity DRSs against various cancer cell types.
HEPG2 MCF-7 U251MG H157 MDA-MB-435S PC-3 Human 
erythrocytes
DRS-B2
DRS-B3
DRS-B4
DRS-PH
DRS-L1
DRS-CA1
DRS-DU1
DRS-PD1
DRS-PD2
DRS-PS4
This table gives an overview of the DRS that have been tested for activity against some human cancer cell lines in vitro. Cells are colored in green if: high activity 
(< 10 μM to reach EC50) was found, orange if: two studies did not agree on high activity, red if they agreed on low activity (> 10 μM to reach EC50), white if: no 
published data was available. In the Human erythrocyte column, the opposite is instinctively true; green color indicates low, and red indicates high activity (van Zoggel 
et al., 2012; Dos Santos et al., 2017; Mor et al., 1994b; Nicolas and El Amri, 2009; Charpentier et al., 1998; Conlon et al., 2007; Galanth et al., 2009; Shi et al., 2016; 
Huang et al., 2017; Zhu et al., 2018)
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initiation of apoptosis via mitochondrial membrane rupture and 
(iii) non-membranolytic modes of action (Ellerby et al., 1999; 
Chen et al., 2001; Deslouches and Di, 2017).
Below, we will elaborate on how DRSs disrupt the lipid bilayer 
of microbes and cancer cells, and which features are possibly 
responsible for DRSs affinity to microbes and cancer cells. 
Additionally, we will discuss how DRSs modulate host immune 
systems and pathogen’s gene expression. Last, we summarize the 
evidence of DRS acting as a receptor (ant)agonist.
Disruption of the Lipid Bilayer
One common feature DRSs often demonstrate is their disruption 
of the lipid bilayer of a target cell. Early evidence for this is the 
depolarization of bacterial membranes in vitro (Fleury and 
Longeron, 1998). To do this, DRSs likely form tetramers in their 
quaternary structure that form toroidal pores. Using the planar 
lipid bilayer technique, it was shown that the DRS peptides 
accumulate in a carpet like manner on the outside of a lipid 
bilayer until a threshold concentration is reached, causing them 
to form pores in which the peptides are intercalated with the 
phospholipid headgroups of the membrane (Duclohier, 2006). 
The selectivity of these pores appears to be determined by the 
phospholipid headgroups of the plasma membrane. The carpet 
of DRSs on the outside of the lipid bilayer as well as tetramer 
channel with intercalated phospholipid headgroups causes the 
membrane to lose its integrity (Yeaman and Yount, 2003). The 
reason why DRS favor binding to some pathogens and tumors is 
still under investigation and several hypotheses exist, discussed 
here are the possible influence of; membrane charge, membrane 
sulfatation and membrane fluidity.
First DRSs are generally rather cationic peptides and thus 
more prone to bind negatively charged membranes. Bacteria 
and cancer cell membranes typically have a net negative charge, 
the former due to negatively charged phospholipids on inner 
(gram negative) and single (gram positive) membranes (Shai, 
2002), the latter due to expression of phosphatidylserine and 
negatively charged mucin proteins (Utsugi et al., 1991; Hoskin 
and Ramamoorthy, 2008). Interestingly, erythrocytes have net 
negatively charged membranes as well, but are generally less 
affected by DRS (Caillon et al., 2013).
Second the sulfatation of glycosaminoglycans (GAG)’s on the 
membrane surface seems to be of high importance for DRS-B2’s 
effectivity against prostate cancer cell lines (PC3) (Dos Santos 
et al., 2017). Low concentrations of Chondroitin Sulfate C (CS-
C), which is a sulfated GAG, contribute to the α-helical shape of 
DRS-B2, which is its biological active form. Interestingly, sulfated 
GAG’s seem to be essential to the effectivity of cell penetrating 
peptides (CPPs) as well (Yang et al., 2014). Furthermore, when 
Zhu et al. (2018) investigated the activity of DRS-DP1 and 2, 
they found that by introducing a TAT (GRKKRRQRRR) peptide 
at the N-terminal, affinity to the cell membrane and interaction 
with GAG’s increased.
Third, cancer cells often have increased membrane 
fluidity and irregularities of cell surface which contributes 
to membrane destabilization and could affect receptor 
binding and other communications between cancer cell and 
environment (Hoskin and Ramamoorthy, 2008). This may 
account for DRSs being more effective against one cancer 
type (PC3) than another (Leuschner and Hansel, 2004; van 
Zoggel et al., 2012a). It has been observed that membrane 
environment with a strong positive curvature strain influences 
the DRS-B2 into a state that facilitates insertion into the 
membrane (Galanth et al., 2009).
Modulation of the Host Immune System
Besides the membrane disrupting activity, DRS likely modulates 
the host defense system as well. By introducing DRS-S1, 
neutrophils of rat and humans stimulate their microbicidal 
activities such as their production of reactive oxygen species 
(Ammar et al., 1998). Moreover, DRS-S9 is chemotactic for 
human leukocytes (Auvynet et al., 2008). On the other hand, 
DRS-S4 has been observed to bind Lipopolysaccharides (LPS), 
which would rather suppress activation of macrophages and 
decrease the production of inflammatory cytokines (Navon-
Venezia et al., 2002). Furthermore, DRS also shows angiostatic 
activities, which may influence tumor growth (van Zoggel et al., 
2010; van Zoggel et al., 2012).
Modulation of the Pathogen’s Gene 
Expression
We previously mentioned that DRSs can permeate membranes of 
different types of cells and cell nuclei, however it is also possible 
that DRS changes gene expression in a pathogen cell as well. 
DRS-S1 Modulates the expression of C. albicans genes, such as 
the Hyphal wall protein 1 (HWP1) gene (Belmadani et al., 2018). 
In vitro, its expression was downregulated which likely accounts 
for the modified cell morphology that was found. Furthermore, 
changes in aspartic protease genes were found.
Interaction with Cell Membrane Receptors
Lastly, it seems unlikely that there is a partner protein on the 
surface or cytoplasm of the tumor cells that can account for the 
effects of DRS. This is illustrated by the example in which DRS-
B2’s activity on PC3 cell lines is almost identical when composed 
of only amino acids in D configuration, (Dos Santos et al., 2017). 
Since receptors are usually stereo-selective, it is unlikely DRS-B2 
works through a receptor. However, there is evidence that some 
DRS can inhibit adenosine triphosphate (ATP) production 
through receptor binding (Laughlin and Ahmad, 2010).
FUTURE PERSPECTIvES
As DRSs act against a wide variety of pathogens and tumor cell 
lines, it is tempting to speculate on their therapeutic potential. 
Nevertheless, current knowledge on DRS is fragmented with 
respect to mechanism of action and diverse with respect to 
pathogens and cancer cell lines studied. Consecutively, we 
will discuss remaining questions on the mechanism of action, 
potential clinical applications and safety.
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Future Research on Available DRSs
For research on DRSs to move forward on the already investigated 
DRSs described in this paper, it is essential to understand the 
mechanism of action of a specific DRS against a pathogen to fine-
tune this DRS into a molecule that can target a specific clinical 
problem. These potential clinical therapies include treatment of 
infections caused by specific micro-organisms, the treatment 
of infections caused by multiple micro-organisms such as skin 
infections, and as a component of cancer treatment. Furthermore, 
we discuss the current use of DRS in biotechnology.
It seems likely that the mode of action of DRSs relies, 
similarly to many AMPs, in part on membrane disruption 
of target cells. Important factors in this include the cationic 
nature of the peptide, and its ability to retain an α-helical shape. 
The presence of certain phospholipids, GAGs, and proteins 
contribute to this. However, the means to identify more of the 
cell membrane factors, including the shape and fluidity of the 
cell membrane are not readily available, and would require 
innovative tools and techniques at the interface of chemistry 
biology and biophysics.
DRSs can be tested for specific clinical problems in vivo. 
For example, some DRSs act against specific, anti-biotic 
resistant pathogens. From Table 1 we can infer that DRS-
B4, DRS-O1, DRS-DI06, DRS-CA1, DRS-DU1, DRS-PD2 
and DRS-PS4 are all promising candidates for specifically 
targeting P. aeruginosa, a pan-resistant bacterium notorious 
for causing severe infections in hospital settings. Another 
example is DRS-O1 which has thus far been the only DRS 
to show activity against the S. mansoni, a neglected tropical 
disease in need of treatment possibilities.
On the other hand, there are some DRSs that can act against 
a range of pathogens. This makes some DRSs ideal for clinical 
applications in which several pathogens need to be targeted. 
Skin infections, for example in diabetic foot ulcers or catheter 
infections are caused by organisms such as gram-positive 
bacteria as well as some fungi (Schittek et al., 2008). From 
Table 1 we can conclude that DRS-S3, DRS-S5, DRS-CA1, 
DRS-DU1, DRS-PS4, DRS-PD2 and DRS-O1 all show activity 
against the S. aureus (some including the methicillin resistant 
variant), as well as the C. albicans fungus, without damaging 
erythrocytes. Gomes and colleagues (2015) have already 
positively assessed DRS’s incorporation in cotton gauzes and 
show potential in fast-release medical applications. Therefore 
they are potential starting points for therapeutic applications 
in skin infections.
Some even speculate that there is potential for DRS as a 
contraceptive, as DRS-S4 is spermicidal (Zairi et al., 2005). 
DRS-S4 shows activity against HIV, and several other genital 
pathogens (Lorin et al., 2005; Savoia et al., 2010). However, it 
appears the recent literature prefers antimicrobials that are within 
(or close to) the human genome for the use as contraceptives 
(Tanphaichitr et al., 2016). Moreover, the clinical relevance of 
such a contraceptive as well as the high degree of effectivity that 
would be demanded are questionable.
There is the potential of DRS as an aiding therapeutic in 
cancer treatment by working in tandem with conventional 
chemotherapies. This idea finds its roots in a hypothesis 
regarding the evolutionary origins of DRSs in frogs. The idea is 
that DRSs function as an accessory protein that lyses cells and 
penetrates tissue to allow effectiveness of other neuromodulators 
and enzymes in frog secretions (Konig et al., 2015). This 
contrasts with the view that DRSs are part of an innate immune 
system. Indeed, there is striking similarity in the amino acid 
sequences of preproDRS and precursors of demorphin and 
deltorphin (Amiche et al., 1994) (which are powerful opioid 
agonists), suggesting these peptides work together to achieve 
a common goal. This idea might extend to clinical practice as 
well. Potentially DRS could be part of a drug delivery system 
and play similar role to other cell penetrating peptides in cancer 
research (Bolhassani, 2011; Bolhassani et al., 2011; Yang et al., 
2014). DRS would penetrate and disintegrate cell membranes of 
specific cancer cells and (attached) conventional cytostatic agents 
may then – more effectively – affect the tumor tissue. Some 
support for this idea comes from a study using Cecropin A and 
conventional chemotherapy on leukemic patients, Cecropin A 
increased the effect of the conventional therapy (Hui et al., 2002). 
Possibly the same idea can be used when targeting microbial 
pathogens (Balaban et al., 2004). Potentially, red blood cells or 
chitosan nanoparticles could function as a potential carrier for 
DRS (Feder et al., 2001; Medeiros et al., 2014).
Meanwhile the field of applied biotechnology has moved 
forward on these developments and researchers have 
incorporated DRS in the genetic material of potato and citrus 
plants. The plants can express these peptides and protect the 
crops from disease (Rivero et al., 2012; Furman et al., 2013). 
More recently, DRS-B1 was modified (N-terminally modified 
and recombined respectively) to protect poplar plants and 
tobacco plants from infections by inserting the DRS protein in 
the genome of the host (Yevtushenko and Misra, 2019; Shams 
et al., 2019). On the one hand pesticides can now be avoided on 
these crops, on the other hand studies already report resistance 
of bacteria to anti-microbial peptides by producing positively 
charged molecules on the membrane and pumping AMP’s 
out of the cells (Joo, Fu & Otto, 2016; Andersson Hughes & 
Kubicek Sutherland, 2016). Genetically altering plants on a 
large scale could potentially endanger DRS’s use as an antibiotic 
in humans.
Lastly, the safety of DRS in humans remains to be investigated. 
Even though several DRS have been administered to mice 
and rats, to our knowledge, no phase-1 clinical trials have 
been conducted on the safety of any DRS in humans thus far. 
Encouragingly, many of the documented short-term adverse 
effects of the Kambo ritual such as nausea and tachycardia can 
be ascribed to other molecules in the cocktail (Erspamer et al., 
1993), nevertheless the safety of the DRS remain to be shown. 
Researchers in many fields could benefit from the knowledge of 
a safe DRS peptide.
Future Research on Novel DRSs
The investigation of other Anuran species is likely to yield 
anti-microbial or DRS like peptides that can contribute  to 
illuminating the mechanism of action of these peptides  and 
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provide starting points for therapeutical treatments. According 
to some estimations, skin compounds have been detected and 
isolated from 400 anuran species, which means that more than 
90% of all documented frog species still await screening (Konig 
et al., 2015). The isolated peptides from different species 
thus far are very often unique and sometimes useful which 
makes it very likely that new, useful and novel biomolecules 
await discovery.
To ensure these new molecules contribute to scientific 
literature in a less fragmented way, it is important to identify 
the questions that remain on the mechanism of action of 
DRS. Whenever a new DRS or a modification is tested, ideally 
these mechanisms should be evaluated: 1) disruption of 
plasma/mitochondrial membranes; 2) necrosis; 3) apoptosis; 
4)  mechanisms of mediated immunity; 5) membrane receptor 
involvement; 6) inhibition of DNA synthesis; 7) anti-angiogenic 
effects (Gaspar et al., 2013). Additionally, their activity against 
human erythrocytes and epithelial cells should be evaluated to 
assess clinical relevance and help understand how DRS recognize 
target cells.
DRS are a complex family of bioactive peptides. Accumulating 
evidence suggests their efficacy in a wide variety of medical 
applications. Despite the still puzzling mechanisms of action, 
DRSs are extremely suitable for specific medical problems.
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